Effect of aflibercept on refractory macular edema associated with central retinal vein occlusion

详细信息    查看全文

• 作者：Michael N. Cohen ; MD^⁎ ; Samuel K. Houston ; MD^⁎ ; ^&dagger ; ; Alexander Juhn ; BA^⁎ ; ^&Dagger ; ; Allen C. Ho ; MD^⁎ ; ^&dagger ; ; Carl D. Regillo ; MD^⁎ ; ^&dagger ; ; James Vander ; MD^⁎ ; ^&dagger ; ; Allen Chiang ; MD^⁎ ; ^&dagger ; ; ^{achiang@midatlanticretina.com" class="auth_mail" title="E-mail the corresponding author}
• 刊名：Canadian Journal of Ophthalmology / Journal Canadien d'Ophtalmologie
• 出版年：2016
• 出版时间：October 2016
• 年：2016
• 卷：51
• 期：5
• 页码：342-347
• 全文大小：1063 K

文摘

To report short-term visual and anatomic outcomes of patients who were switched to aflibercept for persistent macular edema associated with central retinal vein occlusion (CRVO).

Methods

Retrospective, consecutive, interventional case series of 17 patients with persistent macular edema secondary to CRVO (defined as intraretinal edema and either <50 µm reduction in central foveal thickness [CFT] or worsening or no improvement in visual acuity [VA] compared to baseline) despite anti-VEGF treatment who were switched to aflibercept treatment. Main outcome measures included VA, anti-VEGF treatment history, and spectral-domain optical coherence tomography evaluation of macular edema and CFT.

Results

The mean age was 77 years, and the mean VA at CRVO diagnosis was 20/135 with a CFT of 523.4 µm. Mean number of injections before switching to aflibercept was 12.9 (range: 3–40) and mean number of months of anti-VEGF treatment before switching to aflibercept was 18.7. Mean VA at switch to aflibercept was 20/182 (p = 0.50) with mean CFT of 547.9 µm (p = 0.66). Mean aflibercept injections were 4.0, and mean follow-up from switch to last follow-up was 5.2 months. Final mean VA was 20/115 (p = 0.017), with a CFT of 315.2 µm (p = 0.0012). Of the patients, 35.2% gained ≥3 lines. 29% of patients had complete resolution of macular edema, and the mean change in CFT was −233 µm.

Conclusions

Aflibercept appears to have a beneficial effect on anatomic and VA outcomes in a subset of patients with macular edema secondary to CRVO that is refractory to treatment with bevacizumab and/or ranibizumab.